{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:26:32Z","timestamp":1785529592780,"version":"3.56.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100010751","name":"Fondecyt","doi-asserted-by":"publisher","award":["1190419"],"award-info":[{"award-number":["1190419"]}],"id":[{"id":"10.13039\/501100010751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020884","name":"ANID","doi-asserted-by":"publisher","award":["ACT210039"],"award-info":[{"award-number":["ACT210039"]}],"id":[{"id":"10.13039\/501100020884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Primary aldosteronism (PA) treatment with mineralocorticoid receptor antagonists (MRAs) is effective but limited by side-effects and low potency of currently available options. Finerenone, a novel MRA, has emerged as a promising alternative but data in PA are lacking. This report presents a real-world study wherein PA patients on eplerenone were forced to switch to finerenone therapy during a national shortage. During treatment with finerenone, blood pressure and antihypertensive dose remained unchanged, but the proportion of patients with normal blood pressure and complete biochemical response was decreased (P = .004 and P = .008, respectively). The latter was determined by a reduction in direct renin concentration, a biomarker previously associated with increased cardiovascular risk in PA. Although these results could be explained by finerenone's unique pharmacokinetics and mechanism of action, further studies are needed to evaluate longitudinal outcomes associated with these findings and determine its effectiveness in PA treatment.<\/jats:p>","DOI":"10.1093\/ejendo\/lvaf099","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T17:48:11Z","timestamp":1747417691000},"page":"K50-K53","source":"Crossref","is-referenced-by-count":13,"title":["Real-world outcomes of finerenone in primary aldosteronism"],"prefix":"10.1093","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7213-855X","authenticated-orcid":false,"given":"Thomas","family":"Uslar","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Pontificia Universidad Cat\u00f3lica de Chile , Santiago 8330077 ,","place":["Chile"]},{"name":"Program for Adrenal Disorders, Translational Endocrinology Center (CETREN UC) , Santiago 8330033 ,","place":["Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6686-0463","authenticated-orcid":false,"given":"Benjam\u00edn","family":"Sanfuentes","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Pontificia Universidad Cat\u00f3lica de Chile , Santiago 8330077 ,","place":["Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pontificia Universidad Cat\u00f3lica de Chile , Santiago 8330077 ,","place":["Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0314-9252","authenticated-orcid":false,"given":"Anand","family":"Vaidya","sequence":"additional","affiliation":[{"name":"Center for Adrenal Disorders, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School , Boston, MA 02115 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Baudrand","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Pontificia Universidad Cat\u00f3lica de Chile , Santiago 8330077 ,","place":["Chile"]},{"name":"Program for Adrenal Disorders, Translational Endocrinology Center (CETREN UC) , Santiago 8330033 ,","place":["Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"issue":"2","key":"2025052713385658900_lvaf099-B1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.123.066389","article-title":"Subclinical primary aldosteronism and cardiovascular health: a population-based cohort study","volume":"149","author":"Hundemer","year":"2024","journal-title":"Circulation"},{"issue":"11","key":"2025052713385658900_lvaf099-B2","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41574-022-00730-2","article-title":"Primary aldosteronism\u2014a multidimensional syndrome","volume":"18","author":"Turcu","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"2025052713385658900_lvaf099-B3","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1161\/HYPERTENSIONAHA.122.19134","article-title":"Cardiac structure and function across the spectrum of aldosteronism: the atherosclerosis risk in communities study","volume":"79","author":"Brown","year":"2022","journal-title":"Hypertension"},{"issue":"24","key":"2025052713385658900_lvaf099-B4","doi-asserted-by":"publisher","first-page":"e023082","DOI":"10.1161\/JAHA.121.023082","article-title":"Heightened cardiovascular risk in hypertension associated with renin-independent aldosteronism versus renin-dependent aldosteronism: a collaborative study","volume":"10","author":"Hu","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"2025052713385658900_lvaf099-B5","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1210\/clinem\/dgaa606","article-title":"Evolution of the primary aldosteronism syndrome: updating the approach","volume":"105","author":"Vaidya","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025052713385658900_lvaf099-B6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1161\/HYPERTENSIONAHA.120.15006","article-title":"Serum aldosterone concentration, blood pressure, and coronary artery calcium: the multi-ethnic study of atherosclerosis","volume":"76","author":"Inoue","year":"2020","journal-title":"Hypertension"},{"issue":"9","key":"2025052713385658900_lvaf099-B7","doi-asserted-by":"publisher","first-page":"630","DOI":"10.7326\/M17-0882","article-title":"The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study","volume":"167","author":"Brown","year":"2017","journal-title":"Ann Intern Med"},{"issue":"4","key":"2025052713385658900_lvaf099-B8","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1161\/01.HYP.0000258554.87444.91","article-title":"Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample","volume":"49","author":"Newton-Cheh","year":"2007","journal-title":"Hypertension"},{"issue":"2","key":"2025052713385658900_lvaf099-B9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S2213-8587(24)00308-5","article-title":"Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort","volume":"13","author":"Yang","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2025052713385658900_lvaf099-B10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1210\/endrev\/bnad024","article-title":"Biomarkers to guide medical therapy in primary aldosteronism","volume":"45","author":"Hundemer","year":"2024","journal-title":"Endocr Rev"},{"issue":"1","key":"2025052713385658900_lvaf099-B11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1210\/endrev\/bnad026","article-title":"Treating primary aldosteronism-induced hypertension: novel approaches and future outlooks","volume":"45","author":"Mullen","year":"2024","journal-title":"Endocr Rev"},{"issue":"3","key":"2025052713385658900_lvaf099-B12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/ajh\/hpac124","article-title":"The nonsteroidal mineralocorticoid-receptor-antagonist finerenone in cardiorenal medicine: a state-of-the-art review of the literature","volume":"36","author":"Georgianos","year":"2023","journal-title":"Am J Hypertens"},{"issue":"5","key":"2025052713385658900_lvaf099-B13","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025052713385658900_lvaf099-B14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"2025052713385658900_lvaf099-B15","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"2025052713385658900_lvaf099-B16","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"2025052713385658900_lvaf099-B17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1161\/CIRCULATIONAHA.124.071452","article-title":"Efficacy and safety of finerenone in patients with primary aldosteronism: a pilot randomized controlled trial","volume":"151","author":"Hu","year":"2025","journal-title":"Circulation"},{"issue":"31","key":"2025052713385658900_lvaf099-B18","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"issue":"1","key":"2025052713385658900_lvaf099-B19","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1159\/000541441","article-title":"A trial of finerenone in a patient with primary aldosteronism","volume":"49","author":"Karanovic Stambuk","year":"2024","journal-title":"Kidney Blood Press Res"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvaf099\/63212486\/lvaf099.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/192\/5\/K50\/63212486\/lvaf099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/192\/5\/K50\/63212486\/lvaf099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T17:39:02Z","timestamp":1748367542000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/192\/5\/K50\/8133931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvaf099","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,4,30]]}}}